7LBA Safety, activity, and response durability assessment of single agent rovalpituzumab tesirine, a delta-like protein 3 (DLL3)-targeted antibody drug conjugate (ADC), in small cell lung cancer (SCLC)

Conference Paper

Full Text

Published version (via Digital Object Identifier)

Duke Authors

Ready, Neal Edward

Cited Authors

Pietanza, MC; Spigel, D; Bauer, TM; Ready, NE; Glisson, BS; Morgensztern, D; Robert, F; Salgia, R; Kochendorfer, M; Patel, M; Strickland, DK; Govindan, R; Burris, HA; Rudin, CM; Dylla, S

Published Date

September 2015

Published In

European Journal of Cancer

Volume / Issue

51 /

Start / End Page

S712 - S712

Published By

Elsevier BV

International Standard Serial Number (ISSN)

0959-8049

Digital Object Identifier (DOI)

10.1016/s0959-8049(16)31931-1